Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
about
In vitro cardiotoxicity assessment of environmental chemicals using an organotypic human induced pluripotent stem cell-derived model.The Promise and Challenge of Induced Pluripotent Stem Cells for Cardiovascular Applications.21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.A new system for profiling drug-induced calcium signal perturbation in human embryonic stem cell-derived cardiomyocytes.Biomaterial based cardiac tissue engineering and its applicationsLiensinine- and Neferine-Induced Cardiotoxicity in Primary Neonatal Rat Cardiomyocytes and Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.Human Engineered Heart Tissue: Analysis of Contractile ForceSalvianolic Acid A, as a Novel ETA Receptor Antagonist, Shows Inhibitory Effects on Tumor in VitroPluripotent stem cells as a platform for cardiac arrhythmia drug screeningHuman stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.Induced pluripotent stem cells: at the heart of cardiovascular precision medicine.Deconvoluting Kinase Inhibitor Induced Cardiotoxicity.Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.A Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte (hiPSC-CM) Multielectrode Array Assay for Preclinical Cardiac Electrophysiology Safety Screening.Identification of Drug-Drug Interactions In Vitro: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes.Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.Combretastatin A4 disodium phosphate-induced myocardial injury.Machine Learning of Human Pluripotent Stem Cell-Derived Engineered Cardiac Tissue Contractility for Automated Drug Classification.An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.Cytotoxicity of propofol in human induced pluripotent stem cell-derived cardiomyocytes.Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.13th Annual Meeting of the Safety Pharmacology Society: focus on novel technologies and safety pharmacology frontiers.Human pluripotent stem cell-derived cardiomyocyte based models for cardiotoxicity and drug discovery.Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.Stem Cell Research.High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays.Cross-Site Reliability of Human Induced Pluripotent Stem-Cell Derived Cardiomyocyte Based Safety Assays using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study.Multielectrode Array (MEA) Assay for Profiling Electrophysiological Drug Effects in Human Stem Cell-Derived Cardiomyocytes.
P2860
Q32181083-FC0095CC-7FDC-41F8-93D5-7808BE89B604Q33748399-7153E2C9-6E74-4FC7-87C7-34504BEB1E26Q33900003-7D8003CF-66F8-4E51-9A83-5829D3AAB55DQ35181854-2A80FFA3-30B5-4590-B68E-1C962A0A38CEQ35731251-E5AF2AC3-1D84-49FD-A92B-DEE69868373DQ36667033-0F80176A-21F6-4920-85DB-95BCA412CEDCQ36808601-D5497274-52DA-4FFB-952E-FA239D22FDD6Q37094032-80CE4A69-B679-4B58-86B2-EC15428F2023Q37209951-FB84F5C2-5C7E-4A98-BC79-F3DE4768724AQ38235190-1D3F25AC-81FB-4460-83A2-C5515EA5C982Q38240972-3E3FDC70-B8D2-4157-90F0-2E73243D9D7CQ38786687-E9F9302F-B0D6-4A09-B055-2E056F6FD204Q38814429-C04AFA52-F04F-4A03-B693-50C5776D17BFQ39056543-D730693D-279D-4A42-A8E7-543387BD9830Q40233317-D3740BC3-031C-487F-B290-99BC8398FFC8Q40480795-A4B87F0D-03AB-43AD-B4F1-6B8C934810FAQ40640593-63B04A3F-953A-4A8A-9448-C6B47016D0D8Q42398820-18964BB9-22CD-4488-82DD-810322366F27Q45944962-2791A4EC-5AFA-44D6-BB2A-86E3135651B4Q46145054-7E8A7E0F-3E48-4054-B28F-248DB1E8587AQ47216413-D3C00152-CADC-40D1-A3B7-9EB58DDC98BEQ47611653-94195941-814C-431A-8267-7BC4218B1478Q51066704-4C47726B-4285-4268-8C91-965F6AF1AFF7Q51134011-70E97513-4A84-4241-B786-62DBCBD41FEBQ51146786-4DD8E175-4F19-4A88-9CDD-B591221AB350Q53222817-7AAE6840-E16A-42BB-B491-776BBD5AA8DBQ53555497-DF40A497-E2D7-4E21-AA58-6AFCF2677ECCQ53868451-28B04B26-207C-475B-B5AD-0B7A3DCC13C0Q54327084-B5432077-ED62-4987-A131-943F23700188
P2860
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
@en
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
@nl
type
label
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
@en
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
@nl
prefLabel
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
@en
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
@nl
P2093
P2860
P356
P1476
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
@en
P2093
Eric T Chiao
Luke Coyle
Raymond Kemper
Rory M C Abrams
P2860
P304
P356
10.1093/TOXSCI/KFT205
P577
2013-09-19T00:00:00Z